Page last updated: 2024-11-08

tenuigenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tenuigenin: decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12442762
CHEBI ID183955
SCHEMBL ID4031105
MeSH IDM0476096

Synonyms (29)

Synonym
senegin
brn 2714357
27-noro-13-ene-23,28-dioic acid, 12-(chloromethyl)-2-beta,3-beta-dihydroxy-
CHEBI:183955
(2s,3r,4s,4ar,6ar,8as,12as,13s,14ar,14br)-13-(chloromethyl)-2,3-dihydroxy-4,6a,11,11,14b-pentamethyl-2,3,4a,5,6,7,8,9,10,12,12a,13,14,14a-tetradecahydro-1h-picene-4,8a-dicarboxylic acid
2469-34-3
tenuigenin
3-10-00-02482 (beilstein handbook reference)
06s1qh951l ,
unii-06s1qh951l
12-(chloromethyl)-2b,3b-dihydroxy-27
SCHEMBL4031105
AC-34916
Q-100320
senegenin [mi]
27-norolean-13-ene-23,28-dioic acid, 12-(chloromethyl)-2,3-dihydroxy-, (2.beta.,3.beta.,4.alpha.,12.alpha.)-
12-(chloromethyl)-2.beta.,3.beta.-dihydroxy-27-norolean-13-ene-23,28-dioic acid
tenuifolic acid
senegenin, >=98% (hplc)
AKOS037514836
(2s,3r,4s,4ar,6ar,8ar,12as,13s,14ar,14br)-13-(chloromethyl)-2,3-dihydroxy-4,6a,11,11,14b-pentamethyl-2,3,4,4a,5,6,6a,7,8,9,10,11,12,12a,13,14,14a,14b-octadecahydropicene-4,8a(1h)-dicarboxylic acid
HY-N0802
mfcd00466906
27-norolean-13-ene-23,28-dioic acid, 12-(chloromethyl)-2,3-dihydroxy-, (2beta,3beta,4alpha,12alpha)-
CCG-269946
Q27236217
CS-0009808
DTXSID90947632
S9095
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
12alpha-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (9.52)29.6817
2010's31 (73.81)24.3611
2020's7 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.38%)5.53%
Reviews1 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]